Bicocca Open Archive

Logo unimib boa

Farina, F., Ceccon, M., Mori, S., Verga, L., Borin, L., Mologni, L., et al. (2017). Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates. Intervento presentato a: Congress of the European-Hematology-Association JUN 22-25, Madrid, Spain.

Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates

Farina, F
Primo
;Ceccon, M;Mori, S;Verga, L;Borin, LM;Mologni, L;Fontana, D;GEETA, GEETA;Piazza, R;Gambacorti-Passerini, C
Ultimo
2017
abstract + poster
ALK/ALCL, Targeted therapy
English
Congress of the European-Hematology-Association JUN 22-25
2017
HAEMATOLOGICA
2017
102
suppl 2
221
222
P570
http://www.haematologica.org/content/102/s2/1.full.pdf+html
none
Farina, F., Ceccon, M., Mori, S., Verga, L., Borin, L., Mologni, L., et al. (2017). Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates. Intervento presentato a: Congress of the European-Hematology-Association JUN 22-25, Madrid, Spain.
02 - Intervento a convegno
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/205014
Citazioni
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
Social impact